Press Release: DMC Appoints Kelly Smith as VP R&D
- Tuesday, 15 March 2022
15 March 2022 – Kelly Smith, PhD. has joined DMC Biotechnologies as VP R&D. Previously, she was Head of Bioprocessing and Formulation Development at Joyn Bio. Kelly has more than 20 years of experience building and leading research and development teams and has a PhD in Environmental Engineering Science from California Institute of Technology.
Kelly has a broad diversity of experience in both start-up and large companies, including multiple product launches from concept to commercial. She has diverse technical experience across a range of roles and functions, and experience in a variety of product and application areas.
Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “Kelly has exceptional leadership qualities with a track record of building engaged, high-trust and high-results teams. As we expand our operations at DMC, we are excited to welcome Kelly to the team.”
DMC’s technology platform addresses the key barriers that have plagued the biotech industry for decades including standardization, robustness, and predictability across scale. Addressing these challenges translates to a dramatic reduction in the time to market and the investment needed to bring products to commercialization.